![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/05/30/2891113/0/en/Corvus-Pharmaceuticals-to-Present-at-the-Jefferies-Global-Health-Conference.html
https://www.globenewswire.com/news-release/2024/05/06/2876123/0/en/Corvus-Pharmaceuticals-Provides-Business-Update-and-Reports-First-Quarter-2024-Financial-Results.html
https://www.globenewswire.com/news-release/2024/05/02/2874657/0/en/Corvus-Pharmaceuticals-to-Provide-Business-Update-and-First-Quarter-2024-Financial-Results-on-May-6-2024.html
https://www.globenewswire.com/news-release/2024/05/02/2874203/0/en/Corvus-Pharmaceuticals-Announces-Pricing-of-30-6-Million-Registered-Direct-Offering.html
https://www.globenewswire.com/news-release/2024/04/09/2860339/0/en/Corvus-Pharmaceuticals-Announces-Initiation-of-Placebo-Controlled-Phase-1-Clinical-Trial-of-Soquelitinib-for-Atopic-Dermatitis.html
https://www.globenewswire.com/news-release/2024/03/19/2848959/0/en/Corvus-Pharmaceuticals-Provides-Business-Update-and-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html
https://www.globenewswire.com//news-release/2024/03/13/2845827/0/en/Corvus-Pharmaceuticals-to-Provide-Business-Update-and-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-March-19-2024.html
https://www.globenewswire.com//news-release/2024/02/12/2827524/0/en/Corvus-Pharmaceuticals-Presents-Soquelitinib-Preclinical-Data-at-the-Keystone-Symposia-on-Systemic-Autoimmune-and-Autoinflammatory-Diseases.html
https://www.globenewswire.com//news-release/2024/02/08/2826449/0/en/Corvus-Pharmaceuticals-Announces-Orphan-Drug-Designation-Granted-to-Soquelitinib-for-the-Treatment-of-T-Cell-Lymphoma.html
https://www.globenewswire.com//news-release/2024/02/06/2824733/0/en/Corvus-Pharmaceuticals-Appoints-Jeffrey-Arcara-as-Chief-Business-Officer.html